Belcari Giovanni, Conti Alberto, Mazzoni Alessandro, Lanza Maria, Mazzetti Paola, Focosi Daniele
Division of Emergency Medicine, ASL Toscana Nord-Ovest, 56124 Pisa, Italy.
Department of Emergency Medicine, ASL Toscana Nord-Ovest, 56124 Pisa, Italy.
Life (Basel). 2022 Jul 21;12(7):1098. doi: 10.3390/life12071098.
The burden of COVID-19 remains unchanged for immunocompromised patients who do not respond to vaccines. Unfortunately, Omicron sublineages are resistant to monoclonal antibodies authorized in Europe so far, and small chemical antivirals have contraindications and toxicities that have not been studied in these patients. We report here the successful treatment of COVID-19 pneumonia lasting for 4 months after the transfusion of COVID-19 convalescent plasma (CCP) in a patient with severe immunosuppression due to both chronic lymphocytic leukemia and venetoclax treatment. The patient achieved a complete clinical, radiological and virological response after six transfusions (600 mL each) of high-titer CCP collected from triple-vaccinated and convalescent donors. This dramatic case adds to the mounting evidence of CCP efficacy in immunocompromised patients, provided that high-titer and large volumes are infused.
对于对疫苗无反应的免疫功能低下患者，新冠病毒病（COVID-19）的负担依然未变。不幸的是，奥密克戎亚谱系对目前欧洲批准使用的单克隆抗体具有抗性，而小型化学抗病毒药物存在禁忌证且有尚未在这些患者中进行研究的毒性。我们在此报告了一名因慢性淋巴细胞白血病和维奈克拉治疗导致严重免疫抑制的患者，在输注新冠康复者血浆（CCP）后，持续4个月的COVID-19肺炎得到成功治疗。该患者在接受了6次（每次600毫升）从接种三剂疫苗且康复的献血者采集的高滴度CCP输血后，实现了临床、影像学和病毒学的完全缓解。这一显著病例进一步证明了CCP在免疫功能低下患者中的疗效，前提是输注高滴度且大容量的CCP。
